Aid in the diagnosis of acute EBV
Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is a cancer of the nasopharynx, the space behind the nose and above the back of the throat. It is uncommon in most of the world but much more common in southern China, Southeast Asia and North Africa. Most cases are strongly linked to Epstein-Barr virus (EBV). Other risk factors include family history, eating large amounts of salt-cured foods, and smoking. Early symptoms are often subtle: a painless lump in the neck, a blocked nose or nosebleeds on one side, hearing loss or fullness in one ear, and headaches. It is often treated successfully with radiotherapy and chemotherapy.
Lab tests linked to nasopharyngeal carcinoma:
- EBV early antigen (EA) antibody, IgG: an antibody to EBV. It can be raised in NPC, but also during and after ordinary EBV infections, so it isn't diagnostic on its own.
- NPC is diagnosed with a nasal endoscopy and biopsy, then MRI and PET-CT for staging. Plasma EBV DNA is used to support diagnosis, help predict outcome and monitor treatment. In high-risk regions, EBV DNA or EBV IgA antibodies may be used for screening.
How results are read:
- A biopsy confirms NPC.
- A raised plasma EBV DNA before treatment is linked to more extensive disease. A fall to undetectable after treatment is a good sign, and a later rise can signal relapse.
- EBV antibodies are common in healthy adults, so a positive result alone doesn't suggest cancer.
When to see a doctor:
- See a doctor about a neck lump that lasts more than 3 weeks, a blocked nose or nosebleeds on one side, or hearing loss in one ear without a clear cause.
Clinical takeaway: nasopharyngeal carcinoma is diagnosed by biopsy, and plasma EBV DNA is more useful than EBV antibodies for supporting diagnosis and monitoring.
Biomarkers related to this condition
1 marker linked to this condition
Looking for a different marker? Browse all biomarkers →